Osteoconductive Bone Substitutes as Treatment of Benign Lytic Lesions

Abstract:

Benign lytic lesions represent a frequent pathology in our clinic. Regarding therapy, we approach these benign tumors through curettage and filling the defects with bone grafting or bone substitutes like hydroxyapatite crystals and tricalcium phosphate.We want to evaluate the efficiency of both bone grafts and bone substitutes regarding bone consolidation, osseointegration and time until absorption for tricalcium phosphate and hydroxyapatite crystals combination. We analyzed 14 patients treated in our clinic through curettage and defect filling during the last three years: 9 patients’ beneficiated from bone grafting and for the other 5 we used a hydroxyapatite and tricalcium phosphate combination from the same supplier. Diagnoses were bone cyst, non-ossifying fibroma and giant-cell tumor. Therapeutic method was linked with bone graft availability. Follow-up was 24 months through periodical x-ray controls in our clinic. Bone consolidation was satisfactory in all cases with no defect collapse. In conclusion, bone substitutes like combinations of hydroxyapatite crystals and tricalcium phosphate are a useful and safe method for surgical treatment of strictly benign lytic tumors.

• Periodical: Key Engineering Materials (Volume 587)
• Pages: 422-426
• DOI: https://doi.org/10.4028/www.scientific.net/KEM.587.422
• Online since: November 2013
• Authors: Serban Dragosloveanu*, Stefan Cristea, Dan Zaharie
• Keywords: Bone Graft, Bone Substitute, Hydroxyapatite (HA), Lytic Lesions, Tricalcium Phosphate

References

[1] Delloye C, Cnochaert C, Corbu N., Bone substitutes in 2003, an overview. ActaOrthopBelgica 69: 1–8, (2003).

[2] Gouin F, Cappeli M., Aplications cliniques des céramiques phospho-calciques: Biomateriaux de substitution de l'oset du cartilage-. Cahiers d'einseignement de la SOFCOT. Expansion ScientifiqueFrancaise, (1996).

[3] Delecrin J, Takahasi S, Gouin F, Camps C, Passuti N., A synthetic porous ceramic as a bone graft substitute in the surgical management of scoliosis. Spine 25: 563–569, (2000).

DOI: 10.1097/00007632-200003010-00006

[4] Augereau B., Kysteanevrysmal. Tumeur set dystrophies benignes. In: Tomeno B, Forest M (eds) Les tumeur sosseuses de l'appareil locomoteur. Laboratoires UNICET, Paris, (1993).

[5] CERAFORM®: Technical description in Les substitutes osseux en 2005, surl'egide GESTO, p.44, (2005).

[6] Schwartz C, Lecestre P, Fraysinet P, Liss P., Bone Substitutes, Eur.J. OrthopSurgTraum. 9(3): 161–165 , (1999).

DOI: 10.1007/bf00542583

[7] Botez P., Sirbu P., Simion L., Munteanu F., Antoniac I., Aplication of a biphasic macroporous synthetic bone substitutes CERAFORM®: clinical and histological results", Eur.J. OrthopSurgTrauma., 19 : 387-395, (2009).

DOI: 10.1007/s00590-009-0445-7

[8] Botez P, Petcu I., Analyse des applications chez l'homme d'un substitute osseux a base de céramique biphasique (CERAFORM). Étude prospective préliminaire, 8e Congres de l'AOLF, Bucharest, (2002).

[9] Daculsi G, Passuti N., Effect of the macro porosity for osseous substitution of calcium phosphate ceramics, Biomater 11: 86–88, (1990).

[10] Frayssinet P, Trouillet JL, Rouquet N, Autefage A, Delga C et al., Calcium phosphate porous ceramics osseointegration: the importance of a good definition of material specifications. Rev ChirOrthop 79, (1993).

DOI: 10.1016/0142-9612(93)90144-q

[11] Yuan H, Kurashina K, De Brujin JD, Li Y, De Groot K, Zhang X (1999) A preliminary study on osteoinduction of two kinds of calcium phosphate ceramics. Biomaterials 20: 1799–1806.

DOI: 10.1016/s0142-9612(99)00075-7

[12] Van Blitterswijk CA, Grote LL, Kuijpers W, DaemsWTh, De Grout K., Macrospore tissue ingrowths: a quantitative and qualitative study on hydroxyapatite ceramics. Biomateriaux 7: 137–143 , (1986).

DOI: 10.1016/0142-9612(86)90071-2

[13] Gourin F, Delécrin F, Passuti N, Touchait N, Poirier P, Bain JV, Comblement osseux par céramique phosphocalcique biphasée macroporeuse. A propos 23 cas., Revue Chir. Orthop. 81: 59–65, (1995).

[14] Malard O, Bouler JM, Guicheux J, Heymann D, Pillet P, Coquard C, Daculsi G., Influence of biphasic calcium phosphate granulometry on bone ingrowth, ceramic resorbtion and inflamatory reactions. J Biomed Mater Res 46(1): 103–111, (1999).

DOI: 10.1002/(sici)1097-4636(199907)46:1<103::aid-jbm12>3.0.co;2-z

[15] Gautier O, Bouler JM, Aguado E, Legeros RZ, Pilet P, Daculsi G., Elaboration conditions influence physicochemical properties and in vivo bioactivity of macroporous biphasic ceramics. J Mater Sci Mater Med 10(4): 199–204, (1999).

DOI: 10.1023/a:1008949910440

[16] Daculsi G, Passuti N, Martin S, Le Nihouanen IC, Brulliard V, Delécrin I, A comparative study of bioactive calcium phosphate ceramics after implantation in cancellous bone in the dog. Rev ChirOrthop 75: 65–71, (1989).

[17] Saito M, Shimizu H, Beppu M, Takagi M., The role of ß-tricalcium phosphate in vascularized periosteum. J OrthopSci 5: 275–282, (2000).

DOI: 10.1007/s007760050163

[18] Laurie SWS, Kaban LB, Mulliken LB, Murray IE, Donor-site morbidity after harvesting rib and iliac bone. PlastReconstrSurg 73: 933–938, (1984).

DOI: 10.1097/00006534-198406000-00014

[19] Summers BN, Eisenstein SM, Donor site pain from the ilium: A complication of lumbar spine fusion. J Bone Joint Surg 71-B: 677–679, (1989).

DOI: 10.1302/0301-620x.71b4.2768321

[20] Nery EB, LeGeros RZ, Lynch ZL, Lee K., Tissue response to biphasic calcium phosphate ceramic with different ratios of HAIBTCP in periodontal osseous defects. J Periodont 63: 729–735, (1992).

DOI: 10.1902/jop.1992.63.9.729

[21] Khan Y, Yaszemski MJ, Antonios GM, Laurencin C, Tissue engineering of bone: material and matrix considerations. J Bone J Surg Am 90: 36–42, (2008).

DOI: 10.2106/jbjs.g.01260

[22] D. Allison, A. Lindberg, B. Samimi, R. Mirzayan, L. Merendez, A Comparison of mineral bone graft substitutes for bone defects", US Oncology & Hematology.

[23] Gianouddis PV, Dinopoulos H, Tsiridis E (2005) Bone substitutes: an update. Injury 36 (Suppl 3): S20–S27.

DOI: 10.1016/j.injury.2005.07.029

[24] G. El-Adl, M. Mostafa, A. Enan, M. Ashraf, Biphasic ceramic bone substitute mixed with autogenous bone marrow in the treatment of cavitary benign bone lesions", ActaOrthop. Belg., 2009, 75, 110-118.